Company

who We Are

Quinovare is a pharmaceutical-focused drug–device integration company dedicated to needle-free injection technologies.

We work with pharmaceutical partners to enable needle-free delivery formats across development, clinical execution, and product lifecycle evolution—while preserving drug substance, formulation, and core CMC strategies.

Our platform-based approach allows injectable medicines to be translated into executable needle-free formats that align with pharmaceutical development pathways, regulatory expectations, and long-term commercialization plans.

Quinovare’s role is not to redefine the drug, but to expand how injectable therapies can be delivered—safely, consistently, and at scale.

what Makes Quinovare Different

Quinovare is differentiated by how we work with pharmaceutical programs—not by adding device complexity, but by aligning needle-free delivery execution with drug-led development logic. Our approach positions needle-free delivery as a format strategy, rather than treating devices as standalone products.

Pharma-First Execution Orientation
We design needle-free delivery systems to align with pharmaceutical development, regulatory, and lifecycle requirements—rather than requiring drug programs to adapt to device constraints.

Platform-Based, Not One-Off Solutions
Our technologies are developed as scalable platforms, supporting multiple drug programs, indications, and lifecycle stages without restarting development for each project.

Format Innovation Without Drug Modification
Needle-free delivery is enabled without altering drug substance, formulation, or established CMC strategies—reducing development risk and preserving regulatory continuity.

Long-Term Partnership Perspectiv
We collaborate with partners across feasibility, clinical execution, and lifecycle evolution, supporting sustained value creation rather than single-project device deployment.

Working With Quinovar

Quinovare engages with pharmaceutical partners through structured, confidential discussions focused on program fit, execution feasibility, and long-term delivery strategy.
We work collaboratively with development, regulatory, and technical teams to assess how needle-free delivery may support specific development objectives, lifecycle strategies, or new delivery formats—while respecting pharmaceutical ownership of the drug and regulatory pathway.
Whether you are evaluating differentiation for an existing injectable, exploring delivery options for a new program, or assessing needle-free feasibility as part of a lifecycle strategy, we welcome an initial discussion grounded in your specific development context.

Working With Quinovar

Technology Foundation

Quinovare’s needle-free technologies are built on a delivery-first engineering philosophy—prioritizing execution reliability, usability, and pharmaceutical compatibility over device novelty.
Our platform architectures support controlled jet-based delivery across multiple formats and use scenarios, enabling consistent drug administration while preserving established pharmaceutical development frameworks.
At the foundation level, our technology approach emphasizes:

Delivery Mechanism Discipline
Controlled micro-jet delivery engineered to achieve predictable penetration depth, dispersion behavior, and dose consistency across intended administration routes.

Platform Architecture Thinking
Modular, platform-based system design enabling multiple delivery formats and lifecycle configurations without re-engineering
core technology for each program

Injection Science & Use-Context Awareness

Technology development informed by injection mechanics, tissue interaction principles, and real-world use considerations—supporting both technical performance and patient-facing execution.

Regulatory-Aware Engineering

System architecture and development practices structured with drug–device combination expectations in mind,
facilitating alignment with pharmaceutical-led regulatory pathways.

Working With Quinovar

Design Recognition & Industry Validation

Quinovare’s needle-free delivery systems have received international design recognition reflecting execution quality, usability discipline, and system-level coherence.
These recognitions are not positioned as aesthetic achievements, but as external validation of how our platforms address real-world use requirements—where safety, intuitiveness, and reliability are critical to pharmaceutical execution.
Design recognition and industry validation acknowledge:

Human Factors–Driven Design Quality

Independent validation of usability-focused design approaches supporting safe, intuitive interaction across patient and
clinician use contexts.

Execution-Oriented System Integration Recognition of how mechanical performance, form factor, and use workflow are integrated into cohesive delivery systems
rather than isolated device components. Industrial Design Supporting Pharmaceutical Use Design outcomes aligned with pharmaceutical expectations for consistency, repeatability, and scalability beyond conceptual or prototype-level design.

Working With Quinovar

Global Presence & Operations

Quinovare operates with a global collaboration mindset, supporting pharmaceutical programs intended for multi-region development and deployment.
Our core engineering, development, and quality operations are structured to collaborate with pharmaceutical partners across different regulatory environments and use contexts—while maintaining consistency in execution standards, documentation discipline, and project governance.
Key aspects of our global operating approach include:

Centralized Engineering with Global Collaboration

Core technology development and system engineering are centralized to ensure platform consistency, while
collaboration models are designed to support partners and programs across regions.

Multi-Region Program Awareness Experience supporting programs intended for deployment across Asia, Europe, and North America, with awareness of
regional regulatory expectations, use environments, and supply considerations. Operational Readiness for Pharmaceutical Partnerships Internal processes aligned with pharmaceutical collaboration requirements, including confidentiality management, documentation rigor, and cross-functional project coordination.

Scalable Engagement Model Operational structures designed to support progression from early feasibility discussions to clinical and commercial-stage
collaboration without restructuring core teams or processes.